Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Interim CFO Compensation Arrangement
As previously disclosed, on October 18, 2022, the Board of Directors (the
"Board") of P3 Health Partners Inc. (the "Company") appointed Erin Darakjian to
serve as Interim Chief Financial Officer of the Company, effective as of
November 1, 2022, pending the Company's search for a permanent successor
following the resignation of Eric Atkins.
In consideration of her service as Interim Chief Financial Officer, on November
28, 2022, the Company entered into a letter agreement with Ms. Darakjian (the
"Darakjian Letter Agreement"). Under the Darakjian Letter Agreement, Ms.
Darakjian will receive a lump sum payment of $50,000 to be paid in December 2022
. In addition, the Darakjian Letter Agreement provides that Ms. Darakjian's
target annual bonus opportunity will be 50% of her base salary, and that, for
fiscal year 2022, Ms. Darakjian will receive a bonus equal to 50% of her base
salary. In addition, on November 28, 2022, Ms. Darakjian was granted an option
to purchase 100,000 shares of Class A common stock of the Company, 25% of which
will vest on October 18, 2023 (the "Initial Vesting Date"), and the balance
(75%) of which will vest in equal annual installments over the next three years
on each anniversary of the Initial Vesting Date, subject to Ms. Darakjian's
continued employment through the applicable vesting date.
The foregoing description of the Darakjian Letter Agreement does not purport to
be complete and is qualified in its entirety by the terms of the Darakjian
Letter Agreement, a copy of which is filed herewith as Exhibit 10.1 and
incorporated herein by reference.
CFO Appointment
On November 27, 2022, the Board appointed Atul Kavthekar to serve as Chief
Financial Officer of the Company, effective as of December 12, 2022 (the
"Effective Date"). The Board also designated Mr. Kavthekar as the Company's
principal financial officer as of the Effective Date, succeeding Ms. Darakjian
in such role. Ms. Darakjian remains Chief Accounting Officer, Senior Vice
President and principal accounting officer of the Company.
Prior to joining the Company, Mr. Kavthekar, 54, served as Executive Vice
President and Chief Financial Officer of EyeCare Partners, a
clinically-integrated comprehensive eyecare platform, since March 2021. From
July 2020 to March 2021, Mr. Kavthekar served as Chief Financial Officer of
Encyclopedia Britannica, a digital media, publishing and educational curriculum
company. From May 2017 to April 2019, Mr. Kavthekar served as Chief Financial
Officer and Treasurer of Diplomat Pharmacy, Inc., an independent provider of
specialty pharmacy services. Mr. Kavthekar served as Chief Financial Officer of
LivingSocial, Inc., an e-commerce retailer, from June 2015 to December 2016. Mr.
Kavthekar also served as Chief Financial Officer and Head of Corporate
Development for the health and wellness division of Sears Holding Corporation,
which included the Kmart Pharmacy business, from December 2013 to May 2015, and
as Division Chief Financial Officer of e-commerce for Walgreen Co. from December
2009 to December 2013. Prior to these positions, he held a number of positions
in the financial industry, focusing on investment banking and mergers and
acquisitions. Mr. Kavthekar received an MBA from The University of Chicago Booth
School of Business.
In connection with his appointment as Chief Financial Officer, on November 27,
2022, the Company entered into an offer letter agreement with Mr. Kavthekar (the
"Kavthekar Letter Agreement"). Under the Kavthekar Letter Agreement, Mr.
Kavthekar's annual base salary will be $450,000 and his target annual bonus will
be 50% of his base salary. In addition, he will receive a $50,000 signing bonus,
which will be paid on the six month anniversary of the Effective Date (the
"Signing Bonus"), provided that Mr. Kavthekar is continuously employed by the
Company through such date. The Signing Bonus is subject to repayment by Mr.
Kavthekar on a pro-rata basis if his employment terminates for any reason before
the 18-month anniversary of the Effective Date. Mr. Kavthekar also will be
granted an option to purchase 600,000 shares of Class A common stock of the
Company, of which 25% will vest on the first anniversary of the Effective Date
(the "Initial Vesting Date"), and the remaining 75% will vest in equal annual
installments over the next three years on each anniversary of the Initial
Vesting Date, subject to Mr. Kavthekar's continued employment through the
applicable vesting date. In addition, if Mr. Kavthekar's employment is
terminated without cause, he will be entitled to receive a lump-sum severance
payment equal to six months of his base salary, subject to his execution and
non-revocation of a general release of claims and continued compliance with
restrictive covenants.
The foregoing description of the Kavthekar Letter Agreement does not purport to
be complete and is qualified in its entirely by the terms of the Kavthekar
Letter Agreement, a copy of which is filed herewith as Exhibit 10.2 and
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
10.1 Letter Agreement, by and between P3 Health Partners Inc. and Erin
Darakjian
10.2 Letter Agreement, by and between P3 Health Partners Inc. and Atul
Kavthekar
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
© Edgar Online, source Glimpses